The Wall Street Journal (online registration required): AstraZeneca PLC failed to win accelerated approval of a cancer drug in the U.S., dealing a blow to its new drug-development pipeline, a key plank of its defense in fighting off a $120 billion approach from Pfizer Inc. last month.
The company said an advisory committee to the U.S. Food and Drug Administration voted 11 to 2 against accelerated approval of its experimental ovarian cancer drug olaparib in patients with a specific...
The most significant government policy, business, and technology news and analysis delivered to your inbox.
Subscribe Nowi360Gov is an intelligent network of websites and e-newsletters that provides government business, policy and technology leaders with a single destination for the most important news and analysis regarding their agency strategies and initiatives.
Telephone: 202.760.2280
Toll Free: 855.i360.Gov
Fax: 202.697.5045
The most significant government policy, business, and technology news and analysis delivered to your inbox.
Subscribe Now